1-炔丙基哌啶主要作为医药中间体，用于相关药物研发与合成。
医药
路线1：
- 步骤: 向炔丙基溴（8.47mmol）和仲胺（16.94mmol）的DMF混合物中加入K₂CO₃（25.41mmol），室温搅拌10-12h；反应后用冰水淬灭，乙酸乙酯萃取，有机层干燥、减压蒸发溶剂得产物。
- 条件: 碳酸钾；N,N-二甲基甲酰胺；20℃；10-12h
- 收率: 67%
- 参考文献: [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol.24, #7, p.1795-1801；[2] Organometallics, 2011, vol.30, #20, p.5471-5479；[3] European Journal of Medicinal Chemistry, 2015, vol.99, p.36-50；[4] Journal of the American Chemical Society, 2013, vol.135, #34, p.12627-12633；[5] Journal of Medicinal Chemistry, 2001, vol.44, #17, p.2719-2734；[6] Patent: WO2013/178815, 2013, A1；[7] Journal of Organic Chemistry, 1993, vol.58, #19, p.5067-5075；[8] Patent: US2007/197537, 2007, A1；[9] Tetrahedron, 1983, vol.39, #19, p.3101-3106；[10] Journal of Organometallic Chemistry, 1983, vol.244, #4, p.311-318；[11] Acta Chemica Scandinavica, 1998, vol.52, #4, p.480-489；[12] Journal of Medicinal Chemistry, 2011, vol.54, #6, p.1693-1703；[13] Organic Magnetic Resonance, 1980, vol.14, #3, p.161-165；[14] Journal of Chemical Research, Miniprint, 1987, #6, p.1501-1518；[15] Patent: EP1577288, 2005, A1；[16] Journal of Medicinal Chemistry, 2008, vol.51, #4, p.835-841；[17] European Journal of Medicinal Chemistry, 2010, vol.45, #9, p.3803-3810；[18] Bioorganic and Medicinal Chemistry, 2011, vol.19, #7, p.2298-2305；[19] Tetrahedron Letters, 2014, vol.55, #4, p.903-909；[20] European Journal of Medicinal Chemistry, 2014, vol.73, p.295-309；[21] Tetrahedron Letters, 2015, vol.55, #4, p.903-909；[22] European Journal of Medicinal Chemistry, 2015, vol.103, p.269-288；[23] Patent: US2830048, 1954
